FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $156 | +147.6% | 73,642 | +569.5% | 0.00% | +100.0% |
| Q1 2023 | $63 | -100.0% | 11,000 | -15.9% | 0.00% | -66.7% |
| Q2 2022 | $324,000 | -92.0% | 13,076 | -87.5% | 0.00% | -90.0% |
| Q1 2022 | $4,059,000 | -83.5% | 104,705 | -75.1% | 0.03% | -77.6% |
| Q4 2021 | $24,585,000 | +632.6% | 420,190 | +642.2% | 0.13% | +737.5% |
| Q3 2021 | $3,356,000 | -27.1% | 56,614 | +6.7% | 0.02% | -23.8% |
| Q2 2021 | $4,606,000 | +215.7% | 53,071 | +199.9% | 0.02% | +162.5% |
| Q1 2021 | $1,459,000 | +456.9% | 17,699 | +514.8% | 0.01% | +700.0% |
| Q4 2020 | $262,000 | -91.5% | 2,879 | -96.3% | 0.00% | -95.0% |
| Q3 2020 | $3,089,000 | +1945.7% | 77,271 | +1651.8% | 0.02% | +1900.0% |
| Q2 2020 | $151,000 | -73.3% | 4,411 | -82.7% | 0.00% | -80.0% |
| Q1 2020 | $565,000 | +234.3% | 25,435 | +163.9% | 0.01% | +150.0% |
| Q1 2019 | $169,000 | +302.4% | 9,637 | -9.1% | 0.00% | – |
| Q3 2017 | $42,000 | – | 10,596 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |